Stock VCNX VACCINEXPAR
Add to a list
To use this feature you must be a member
Log inSign up

All News VACCINEXPAR

Equities

VCNX

US9186403013

Market Closed - Nasdaq
Other stock markets
 03:39:19 2024-04-25 pm EDT 		5-day change 1st Jan Change
5.931 USD +18.50% Intraday chart for VACCINEXPAR +23.56% -36.27%
Apr. 12 Vaccinex, Inc. announced that it has received $1.75 million in funding CI
Apr. 02 Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vaccinex, Inc. announced that it has received $1.75 million in funding
CI
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
AQ
Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Vaccinex, Inc. announced that it expects to receive $1.75 million in funding
CI
Vaccinex, Inc. announced that it has received $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C
CI
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
AQ
Vaccinex, Inc. announced that it expects to receive $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C
CI
Vaccinex, Inc. announced that it expects to receive $1.49961 million in funding
CI
Vaccinex, Inc. Announces Chief Financial Officer Changes, Effective March 14, 2024
CI
Vaccinex, Inc. Announces Executive Changes, Effective March 14, 2024
CI
Sector Update: Health Care Stocks Slipping Wednesday Afternoon
MT
Vaccinex Shares Rise as Company Announces Eight New Deals for Antibody Discovery Platform
MT
Vaccinex, Inc. Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology
CI
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
AQ
Vaccinex, Inc. Announces Reverse Stock Split
AQ
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
AQ
Vaccinex, Inc. announced that it expects to receive $3.700126 million in funding
CI
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
AQ
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VCNX Stock
  4. News VACCINEXPAR